An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many
diseases. GSK239512 is a drug that binds to the Histamine 3 receptor (a protein) in the brain
(receptor occupancy). This study will use the technique of positron emission tomography (PET)
as an imaging tool to highlight areas of the brain that GSK239512 has penetrated, and
subsequently bound to receptors, after receiving an oral dose of the drug. It will also look
at the rate the drug dissociates from the receptors in the brain. Results from the study will
provide information on doses of the drug to be given in further studies.